Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis.

Conclusion: There is a significant increase of developing hypertension in prostate cancer patients treated with abiraterone. Appropriate monitoring and management is strongly recommended to reduce the risk of cardiovascular events and treatment interruptions. PMID: 31168403 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Hypertens Source Type: research